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Background: The Patient and PRovider Interventions for Managing Osteoarthritis (OA) in Primary Care (PRIMO)
study is one of the first health services trials targeting OA in a multi-site, primary care network. This multi-site
approach is important for assessing generalizability of the interventions. These analyses describe heterogeneity in
clinic and patient characteristics, as well as recruitment metrics, across PRIMO study clinics.
Methods: Baseline data were obtained from the PRIMO study, which enrolled n = 537 patients from ten Duke
Primary Care practices. The following items were examined across clinics with descriptive statistics: (1) Practice
Characteristics, including primary care specialty, numbers and specialties of providers, numbers of patients age
55+, urban/rural location and county poverty level; (2) Recruitment Metrics, including rates of eligibility, refusal and
randomization; (3) Participants’ Characteristics, including demographic and clinical data (general and OA-related);
and (4) Participants’ Self-Reported OA Treatment Use, including pharmacological and non-pharmacological therapies.
Intraclass correlation coefficients (ICCs) were computed for participant characteristics and OA treatment use to
describe between-clinic variation.
Results: Study clinics varied considerably across all measures, with notable differences in numbers of patients age
55+ (1,507-5,400), urban/rural location (ranging from “rural” to “small city”), and proportion of county households below
poverty level (12%-26%). Among all medical records reviewed, 19% of patients were initially eligible (10%-31% across
clinics), and among these, 17% were randomized into the study (13%-21% across clinics). There was considerable
between-clinic variation, as measured by the ICC (>0.01), for the following patient characteristics and OA treatment use
variables: age (means: 60.4-66.1 years), gender (66%-88% female), race (16%-61% non-white), low income status (5%-27%),
presence of hip OA (26%-68%), presence both knee and hip OA (23%-61%), physical therapy for knee OA (24%-61%) and
hip OA (0%-71%), and use of knee brace with metal supports (0%-18%).
(Continued on next page)* Correspondence: kdallen@email.unc.edu
1Health Services Research and Development Service, Durham VA Medical
Center, Durham, NC, USA
2Department of Medicine and Thurston Arthritis Research Center, University
of North Carolina, Chapel Hill, NC, USA
Full list of author information is available at the end of the article
© 2014 Allen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Allen et al. BMC Musculoskeletal Disorders 2014, 15:413 Page 2 of 12
http://www.biomedcentral.com/1471-2474/15/413(Continued from previous page)
Conclusions: Although PRIMO study sites were part of one primary care practice network in one health care system,
clinic and patient characteristics varied considerably, as did OA treatment use. This heterogeneity illustrates the
importance of including multiple, diverse sites in trials for knee and hip OA, to enhance the generalizability and evaluate
potential for real-world implementation.
Trial registration: Clinical Trial Registration Number: NCT 01435109
Keywords: Osteoarthritis, Health services, Multicenter studyBackground
Knee and hip osteoarthritis (OA) are among the most
common chronic health conditions and leading contribu-
tors to pain and disability among adults [1-6]. The preva-
lence of OA is on the rise, and this trend is expected to
continue [7]. For example, recent data from the Framing-
ham Osteoarthritis Study show that over the past 20 years,
the prevalence of knee OA approximately tripled in men
and almost doubled in women [8]. Therefore, in addition
to the substantial toll of OA at the individual level [9], this
health problem is a significant burden for healthcare sys-
tems [10-12].
Evidence-based guidelines emphasize that adequate
management of knee and hip OA requires a combination
of behavioral and clinical strategies [13-16]. However,
many studies show there is underutilization of core treat-
ment approaches [12,17-21]. For example, although
weight management and physical activity are key compo-
nents of managing knee and hip OA [13,15,16], the major-
ity of adults with OA are overweight and physically
inactive [17,22,23], and provider recommendations for
these behavioral strategies are infrequent [19,24-26]. With
respect to clinical care, several studies have shown low
pass rates for OA quality of care indicators, including as-
sessment of pain and function, referrals to other providers
(when indicated), appropriate prescribing of pain medica-
tions, and general use of non-pharmacological treatments
[20,27-30]. These data all highlight the need for evidence-
based interventions to augment the use of behavioral
strategies and recommended components of clinical care
for patients with knee and hip OA, with the ultimate goal
of improving pain, function, and other key outcomes.
The Patient and PRovider Interventions for Managing
Osteoarthritis in Primary Care (PRIMO) study is being
conducted to address these gaps. Since optimal manage-
ment of OA is multifactorial in nature, PRIMO is designed
to simultaneously test both patient-based and provider-
based interventions [31]. The provider-based intervention,
which delivers patient-specific treatment recommenda-
tions to providers at the point of care, is particularly in-
novative; only a few studies have examined provider-based
programs to enhance management of OA in clinic settings
[32-34], and none have been in the U.S., to our knowledge.A particularly important feature of PRIMO is that it is be-
ing conducted in multiple primary care clinics. This is im-
portant for assessing generalizability of the interventions
and for understanding whether patient or clinic character-
istics may influence the feasibility and effectiveness in
real-world practice.
In this manuscript we focus on describing the variation
in patient and practice characteristics across the ten
clinics included in PRIMO. There are four specific objec-
tives. First, we report on practice-related and geographic
variables across study clinics. Second, we present recruit-
ment data for each study site. Third, we report on partici-
pant demographic and clinical characteristics across study
sites. Fourth, we describe the use of various OA treat-
ments at baseline across the study sites. Understanding
how OA treatment use may differ across sites is important
for the proposed study because the provider-based inter-
vention aims to enhance use of guideline-based treat-
ments [13-16]. In addition, these data are important
because very little is known about patterns and variability
in OA treatment in the primary care setting. Although
some studies have described OA-related care in other
countries [35-37], data are sparse for the U.S., particularly
with respect to non-pharmacological care [38-40].Methods
Overview and study design
Detailed methods of the PRIMO study have been published
previously [31]. Here we provide an overview of methods
relevant to these analyses. PRIMO is a randomized con-
trolled trial with a 2 × 2 factorial design, in which primary
care clinics are randomized to Provider Intervention vs.
Control, then patients within those clinics are assigned to
Patient Intervention vs. Control. Patients were therefore
assigned to one of four study arms: 1.) Patient Intervention
Only, 2.) Provider Intervention Only, 3.) Patient Interven-
tion + Provider Intervention and, 4.) Usual Care Control.
This research was conducted in compliance with the
Helsinki Declaration and was approved by Duke University
Medical Center Institutional Review Board (Protocol #
Pro00022836). All study participants provided written in-
formed consent prior to study participation.
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This study is being conducted in ten clinics from the Duke
Primary Care Research Consortium, a practice-based re-
search network composed of 30 practices in eight counties
of North Carolina. The PRIMO sites were selected to en-
compass a range of clinics in terms of primary care spe-
cialty (Family Medicine and Internal Medicine), patient
panel size, number and types of providers, and urban/rural
locations. We matched pairs of clinics based on these
characteristics and randomized one of each pair to Pro-
vider Intervention vs. Provider Control.
Participants
We aimed to enroll 56 patients per clinic, for a total sam-
ple size of n = 560. However, as shown in Table 1, we were
unable to meet this recruitment goal at two clinics, and
we enrolled 1 additional patient at 2 clinics because of
overscheduling. Inclusion criteria were: diagnosis of knee
or hip OA (based on physician interpretation of radio-
graphic or magnetic resonance imaging, − documented in
the Duke electronic medical records/for either joint OR
meeting American College of Rheumatology clinical cri-
teria for knee OA [41]), current symptoms in the joint(s)
with OA, body mass index (BMI) ≥ 25, and not currently
meeting Departments of Health and Human Services
physical activity recommendations [42]. Key exclusion cri-
teria were: other rheumatologic conditions, hip or knee
surgery or acute meniscus or anterior cruciate ligament
tear in the past six months, recent hospitalization for car-
diovascular/cerebrovascular event, serious mental health
conditions, on waiting list for hip or knee arthroplasty,
motor neuron diseases, terminal illness, and current par-
ticipation in another OA intervention or lifestyle changes
study. A detailed list of exclusion criteria is available else-
where [31].
Recruitment procedures
All primary care providers at each PRIMO clinic were
approached regarding participation. Providers were given
a summary of the study, and signed a consent form ifTable 1 Characteristics of study clinics
Clinic 1 Clinic 2 Clinic 3 Clinic 4 Cl
Family (FM) or Internal
Medicine (IM)
FM FM FM IM
# Medical Doctors and
Doctors of Osteopathy
6 3 6 8
# Nurse Practitioners and
Physician Assistants
1 4 0 0
# Patients Age 55+ 2,730 5,400 2,865 4,859 2
Urban/Rural Setting* Rural Rural Rural Sm City R
% Households Below
Poverty Level in County
19.9% 25.8% 16.4% 19.3% 1
*Lg (large) city = population >250,000; Sm (small) city = population 100,000-250,000willing to participate. Most providers participated, but
two providers at one clinic and one provider at another
clinic declined participation. We used Duke electronic
medical records to identify patients of participating pro-
viders who had ICD-9 codes for knee/hip OA (715.xx)
and knee/hip pain (719.xx); in three clinics (#1, #7, and
#10 in Table 1) we also expanded the codes to include
pain in a limb (729.5) because we did not meet enroll-
ment goals with the first two sets of codes. We also ini-
tially restricted this search to patients who had a visit at
study clinics within the past 12 months, to help identify
those who were regular patients at these sites; for eight
clinics (all but clinics #5 and #9 in Table 1) we then ex-
tended this window to 18 months in order to meet en-
rollment goals. Following these data pulls, we further
examined patients’ medical records to confirm the pres-
ence of an OA diagnosis (based on criteria noted above)
and to check for exclusion criteria. We mailed introduc-
tory letters, signed by patients’ primary care providers,
to those who met criteria based on the electronic med-
ical record, followed by a screening telephone call to fur-
ther assess eligibility. Patients who met those screening
criteria were then asked to meet a study team member
at their clinic site, where we assessed clinical criteria for
knee OA (when appropriate) [41], as well as height and
weight to determine BMI. Patients who were not over-
weight or did not meet clinical criteria for knee OA (and
also did not have radiographic evidence of knee or hip
OA in at least one joint) were excluded from the study.
Interventions
Patient intervention
This is a twelve-month intervention that focuses on three
key behaviors important for managing OA [13,15,16,43]:
physical activity, weight management, and cognitive be-
havioral pain management skills. The intervention is deliv-
ered via telephone by a health educator, with calls
scheduled twice per month for the first six months, then
monthly for the last six months. The intervention delivers
educational content and emphasizes goal-setting andinic 5 Clinic 6 Clinic 7 Clinic 8 Clinic 9 Clinic 10 Average
FM IM IM IM FM FM N/A
5 8 8 7 9 6 6.4
2 0 0 0 2 1 1.1
,720 4,590 4,259 2,916 3,817 1,507 3,566
ural Sm City Sm City Lg City Sm City Town N/A
6.4% 19.3% 19.3% 11.6% 19.3% 16.4% 13.5%
; Town = population 20,000-99,999; Rural = population <20,000.
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three months of the study, participants are asked to choose
to focus on either weight management or physical activity;
the other topic is covered for the second three months.
During the final six months of the intervention, participants
continue to work on goals related to physical activity and
weight management. Cognitive behavioral pain manage-
ment skills are taught and reinforced throughout the inter-
vention. Participants also receive written educational
materials, an OA exercise video and accompanying therapy
band, and a CD of relaxation exercises.
Provider intervention
This intervention involves delivery of patient-specific OA
treatment recommendations, based on published guidelines
[14-16,44], delivered at the point of care. The recommenda-
tions include both non-pharmacological and pharmaco-
logical therapies [31]. The study team and other content
experts developed algorithms to guide which treatment rec-
ommendations would be appropriate for a given patient.
Clinical data that feeds into these algorithms are derived
from medical records and baseline assessments with each
participant. The patient-specific treatment recommenda-
tions are delivered to primary care providers prior to partic-
ipants’ first routine (non-urgent) visit after enrolling in the
study. Recommendations are delivered to providers within
the electronic medical record system.
Measures
All measures for these analyses were obtained as part of
the recruitment process and baseline assessments.
Clinic Data included primary care specialty (Family or
Internal Medicine), numbers of physicians (medical doctor
(MD), doctor of osteopathy (DO)) and mid-level providers
(e.g., physician assistant (PA), nurse practitioner (NP)) at
the time enrollment began at the clinic, number of pa-
tients age 55 years or older (since this is a key risk demo-
graphic for lower extremity OA [45]) with at least one
visit in 2010 (start of the study), geographic setting (large
city, small city, town, or rural) based on US Census Bur-
eau definitions [46], and proportion of households in the
county with income below poverty level [47].
Participant Recruitment Data included, for each site,
the numbers of medical records reviewed and the num-
bers of patients who were: mailed a recruitment letter, not
pursued after the recruitment letter was mailed, refused
participation prior to randomization, were found to be in-
eligible prior to randomization, and were randomized.
Patient Demographic and Clinical Characteristics in-
cluded age, gender, race (white vs. non-white), marital sta-
tus (married/living with partner vs. other), self-reported
income status (low income defined as “just meet basic ex-
penses” or “don't have enough to meet basic expenses”),
self-reported general health (excellent, very good, good vs.fair, poor), body mass index (BMI), Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) –
a measure of pain, stiffness and function (range of 0–96
with higher scores indicating worse symptoms) [48,49],
presence of knee OA, hip OA or both (determined as de-
scribed above for inclusion criteria), and self-reported dur-
ation of OA symptoms.
Osteoarthritis Treatment Variables included self-reported:
current use of any pain medication for OA (as well as spe-
cific classes including non-steroidal anti-inflammatory drugs
(NSAIDs) and opioid and non-opioid analgesics), ever hav-
ing used a topical cream for OA, ever having a knee or hip
joint injection (separately), ever having seen a physical ther-
apist (PT) for knee or hip OA (separately), ever having used
any knee brace and use of knee braces with metal supports
(if participants had knee OA), ever having used herbs or
supplements for OA.
Analyses
Descriptive statistics were calculated by clinic. Means and
standard deviations were calculated for continuous vari-
ables and proportions for dichotomous variables. Intraclass
correlation coefficients (ICCs) were used to measure
between-clinic variation in patient characteristics and OA
treatment use. Substantial between-clinic variation is indi-
cative of within-clinic homogeneity or a clustering effect.
ICCs were calculated using random effects models [50,51].
Results
Characteristics of study clinics
As shown in Table 1, this study included a diverse set of
primary care clinics. Six were Family Medicine and four
Internal Medicine clinics, with a range of 3–9 MD or DO
providers and a range of 0–4 mid-level providers (NP,
PA). The mean number of patients age 55 or older was
3,566, with a range of 1,507-5,400. Clinic locations ranged
from rural to large city settings, and proportions of county
households with income below poverty level ranged from
12%-26%.
Recruitment data
Figure 1 describes the overall flow of participants into the
study. From n= 16,393 individuals initially identified from
Duke electronic medical records, based on ICD-9 codes,
n = 2,315 were screened, and n = 537 were found to be eli-
gible, agreed to participate in the study and completed base-
line assessments. As shown in Table 2, the study team
reviewed a large number of medical records to meet enroll-
ment goals for this study. Overall, records of 16,393 poten-
tially eligible patients (based on ICD-9 codes) were
reviewed, ranging from 1,185-2,412 across clinics. There
were substantial differences across clinics with regard to pa-
tients who were eligible based on medical record review; this
is illustrated by the proportion of patients who were mailed
Participating Duke 
Primary Care Clinics 
(n=10) 
OA Intervention Clinics 
(n=5) 
 Usual Care Clinics 
(n=5) 
Patients Identified 
from Medical Records 
(n=8319) 
Patients Identified 
from Medical Records 
(n=8074) 
Screened 
(n=1202) 
Screened 
(n=1113)
Screened Eligible 
(n=356) 
Screened Eligible 
(n=315)
Consented, 
Baseline Completed, 
 & Randomized 
(n=280)
Consented, 
Baseline Completed, 
& Randomized 
(n=257)
Ineligible: 6681 
Declined: 234 
Not Pursued: 202 
Ineligible: 6517 
Declined: 257 
Not Pursued: 187 
Ineligible: 213 
Declined: 633 
Ineligible: 192  
Declined: 606 
Ineligible: 16 
Declined: 60 
Ineligible: 9 
Declined: 49 
Figure 1 CONSORT Diagram of flow of participants into the study.
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ranged from 10%-31%. Of those who were mailed re-
cruitment letters, 58% refused participation prior to
randomization (either by directly notifying the study
team or failing to respond after multiple recruitmentTable 2 Recruitment process variables across ten study clinics
Clinic 1 Clinic 2 Clinic 3 Clinic 4 Cl
# Medical records reviews 1,532 1,369 1,579 1,883 1
# Recruitment letters sent* 319 431 335 355
(21%) (31%) (21%) (19%) (
# Patients refused before
randomization†
210 294 190 210
(65%) (68%) (56%) (59%) (
# Patients ineligible before
randomization†
43 73 63 63
(14%) (17%) (19%) (18%) (
# Patients not pursued
after letter sent† ‡
10 8 26 26
(3%) (2%) (8%) (7%) (
# Patients randomized† 56 56 56 56
(18%) (13%) (17%) (16%) (
*Percent of medical records reviewed. †Percent of patients who were mailed a recruphone calls), and this ranged from 48%-68% across
clinics. An average of 19% of those mailed recruitment
letters were subsequently found to be ineligible prior to
randomization, and this ranged from 14%-26% across
clinics. Overall, 17% of patients who were mailedinic 5 Clinic 6 Clinic 7 Clinic 8 Clinic 9 Clinic 10 Average
,561 1,185 1,638 1,547 1,687 2,412 1,639
340 326 307 223 305 233 317
22%) (28%) (19%) (14%) (18%) (10%) (19%)
163 178 160 141 157 136 184
48%) (55%) (52%) (63%) (52%) (58%) (58%)
62 80 79 35 52 57 61
18%) (26%) (26%) (16%) (17%) (25%) (19%)
58 11 12 0 40 0 19
17%) (3%) (4%) (0%) (13%) (0%) (6%)
57 57 56 47 56 40 54
17%) (18%) (18%) (21%) (18%) (17%) (17%)
itment letter. ‡Due to enrollment goal being met.
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domized into the study, and this ranged from 13%-21%
across clinics.
Participant demographic and clinical characteristics
Table 3 describes participant demographic and clinical
characteristics for the study sample overall. The mean
age of participants was over 60, and these ranged from
60.4 to 66.1 years (Table 3 and Figure 2). The proportion
of female participants ranged from 66%-88%. Propor-
tions of married patients ranged from 43%-65%, and the
proportions with self-reported low income spanned 5%-
27%. In terms of clinical and health-related characteris-
tics, 10%-35% of participants reported having “fair” or
“poor” overall health, and the mean BMI ranged from
33.5-37.2 kg/m2. The mean WOMAC score acrossTable 3 Participant characteristics and self-reported OA
treatment use: total sample*
Mean (SD) or %
Mean age (SD) 63.2 (9.6)
% Female 73.9
% Non-white 39.6
% Married, living with partner 58.9
% Low income 17.7
% with Fair/Poor self rated health 19.9
Mean BMI (SD) 35.6 (7.4)
Mean WOMAC (SD) 38.6 (17.0)
Joints with OA
% with Knee OA 95.2
% with Hip OA 49.5
% with Knee & Hip OA 44.9
Mean Duration of Arthritis Symptoms (SD) 10.4 (9.2)
Medications for OA
% Using any pain medication 82.1
% Using analgesic 23.7
% Using NSAID 56.2
% Using opioid 13.0
% ever used topical creams for OA 57.0
% ever had knee joint injection* 55.4
% ever had hip joint injection† 19.4
% ever seen physical therapist for knee arthritis* 39.1
% ever seen physical therapist for hip arthritis† 34.0
% ever used knee brace* 52.9
% ever used knee brace with metal supports^ 22.6
% used herbs / supplements 19.7
*From among participants with knee OA; †From among participants with hip
OA. ^Among patients who have knee OA and reported using a knee brace.
2 patients were missing race data,,1 patient was missing the WOMAC, 1
patient was missing the duration of arthritis symptoms, and 2 patients were
missing data on topical creams.clinics was 38.6, which indicates mild to moderate OA
symptoms; scores ranged from 34.7-44.2 across clinics.
Most patients at all clinics (90%-98%) had a diagnosis of
knee OA, 26%-68% had a diagnosis of hip OA, and 23%-
61% had both diagnoses. The mean duration of self-
reported arthritis symptoms ranged from 7.7-12.5 years.
ICCs indicated considerable between-clinic variation
(>0.01) for gender, age, race, low income status, hip OA
diagnosis, and combined knee and hip OA diagnoses (see
Figure 2). There was lower, but potentially meaningful
between-clinic variation (ICCs ≤ 0.01) for marital status,
BMI, overall health status, WOMAC score, and duration
of OA symptoms. There was no estimable between-clinic
variation in diagnosis of knee OA (ICC = 0), indicative of
no clustering effect for knee OA diagnosis.
OA treatment Use
Table 3 describes participants’ self-reported OA treat-
ment use for the study sample overall. The majority of
patients at all clinics reported current use of some type
of medication to manage their OA symptoms (70%-88%;
Table 3 and Figure 3). Use of specific medication classes
ranged considerably. NSAIDs were used by 47%-64% of
patients, opioid analgesics were used by 4%-19%, and
other analgesics were used by 11%-30%. Many patients
also reported ever having used topical creams for their
OA (46%-66%). Knee joint injections (ever) were re-
ported by 43%-70% of participants with knee OA, and
hip joint injections by 11%-67% of participants with hip
OA. There was a wide range in proportions of patients
with knee OA who reported ever seeing a physical ther-
apist (25%-61%), as well as proportions of those with hip
OA who had seen a physical therapist (0%-71%). Among
those with knee OA, 40%-64% reported using some type
of brace, but only 0%-18% reported ever using a brace
with metal supports. Overall, 20% reported using herbs
or supplements to treat their OA, and this ranged from
14%-32% across clinics.
ICCs indicated considerable between-clinic variation
for use of any pain medication (including all classes), PT
for knee OA, PT for hip OA, and braces with metal sup-
ports for knee OA (see Figure 3). There was lower but
potentially meaningful between-clinic variation (ICCs ≤
0.01) for use of non-opioid analgesics and herbs or sup-
plements. There was no estimable between-clinic vari-
ation in use of NSAIDS, opioids, topical creams, joint
injections for knee and/or hip, or knee brace (ICC = 0),
indicative of potentially no clustering effect for these
treatment uses.
Discussion
A novel and important component of the PRIMO study is
the inclusion of a large number of primary care clinics. To
our knowledge this is the first US-based clinical trial to
Figure 2 Participant demographic and clinical characteristics by study clinic. Notes: Missing data for Race (n = 2), BMI (n = 1), WOMAC (n = 1),
Duration of OA Symptoms (n = 1).
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tiple primary care sites. The PRIMO study clinics varied in
important aspects including practice type (Family vs. In-
ternal Medicine), size, and geographic setting. It is particu-
larly important that the PRIMO study included clinics that
varied in terms of urban/rural location and poverty level, as
these factors can have an impact on the availability of some
components of OA treatment, such as physical therapy ser-
vices. Indeed, we found that some components of self-
reported OA treatment use, particularly physical therapy
for knee OA, tended to be lower among the three PRIMO
clinics in rural locations (e.g. clinics #1, #2 and #5). This
highlights the need for strategies to provide physical ther-
apy services for patients in these underserved areas, since
this is a core treatment component for knee OA.
Our data on recruitment processes illustrates the consid-
erable effort involved in enrolling patients for this pragmatic
clinical trial. Many clinical trials of behavioral interventions
for patients with OA have utilized primarily self-referral
mechanisms for enrollment [52-56]. We chose to actively
enroll patients, via recruitment letters and telephone calls,
because self-referral mechanisms may attract the most
motivated patients, which may affect generalizability and
overestimate intervention effectiveness when applied in real-
world clinical settings. However, the type of activeenrollment we utilized was very time and labor intensive. As
shown in Table 2, 17% of patients who were invited to par-
ticipate in the study via letter were randomized into the
study.
Our recruitment process also differed from most prior
OA clinical trials with respect to verification of diagno-
ses. Prior studies have typically either conducted de novo
imaging to verify an OA diagnosis or relied solely on
self-report of OA. The former is often impractical for
large health services trials like PRIMO, and because we
were delivering OA-specific recommendations to pri-
mary care providers, we chose not to rely exclusively on
self-reported OA diagnosis, which may not have a high
degree of accuracy. Therefore, study team members
spent a considerable amount of time reviewing medical
records to ensure that patients had a prior OA diagnosis,
based on prior imaging (or, for knee OA, physician diag-
nosis plus meeting clinical criteria at the baseline visit
[41]). As shown in Table 2, the study team reviewed over
16,000 medical records, with only 19% meeting initial
eligibility criteria. One factor contributing to the high
volume of records reviewed was inconsistent coding of
OA in the medical record, resulting in the need to re-
view records with a broad range of codes (e.g., “joint
pain” instead of “osteoarthritis”) that encompass many
Figure 3 Self-reported OA treatment use by study clinic. Notes: Items on physical therapy, joint injections, and knee braces asked only of
participants with affected joints. Missing data for Topical Creams (n = 3) and Herbal Supplements (n = 1).
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rithms to identify patients with OA and other rheumatic
conditions based on medical record data. Among algo-
rithms used to identify people with OA, the specificity
has been lower than would be optimal to rely solely on
this information for inclusion on a clinical trial. How-
ever, these algorithms could be used as an initial step to
identify patients who likely have OA, with additional
screening conducted only for those individuals; this may
be a more efficient approach that reduces the time re-
quired for medical record review [57]. More reliable
coding of OA in health care settings would also have a
tremendous positive impact on researchers’ ability to ef-
ficiently identify patients with this health condition for
large health services studies.
Our recruitment data also illustrate considerable het-
erogeneity across study clinics. First, there were differ-
ences in the proportions of patients who were eligible
based on medical record review, ranging from 10%-31%;
this was due to differences both in the presence/absence
of OA diagnoses and exclusionary health conditions.
Second, although the overall randomization rates of
those mailed recruitment letters were relatively similar
across clinics (13%-21%), there was variability in termsof whether more patients were found to be ineligible
(14%-26%) vs. refused participation (48%-68%). As noted
above, in order to meet recruitment goals at some
clinics, we expanded the list of ICD-9 codes and/or the
time window for time of last visit at the clinic. Based on
conversations with providers at these clinics, we believe
the need to expand the list of ICD-9 codes was largely a
reflection of variations in coding practice; some pro-
viders tended to use more general joint pain related
codes (e.g., 719.xx or 729.5) vs. OA-specific codes (715.
xx) regardless of the severity or stage of disease. Al-
though it is possible that use of different code sets across
clinics could have led to variation in OA severity we did
not see clear evidence of this with respect to baseline
WOMAC scores. Specifically, the three clinics at which
we expanded to more general codes were not among
those with the lowest symptom severity (Figure 3). There
were only two clinics in which we did not need to ex-
pand the time window since the prior clinic visit from
12 to 18 months. Patients in these two clinics overall
may have had more frequent visits to providers, possibly
indicating overall poorer health. In one of these clinics
(#5), we did find the highest proportion of study partici-
pants with “fair or poor” general health. Given the
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clinics, it will be important for future analyses of this
study to consider these variations in statistical models.
There was also considerable variability in patient demo-
graphic and clinical characteristics across PRIMO clinics,
further enhancing generalizability of the study. With re-
spect to demographic characteristics, there was substantial
between-clinic variation in age, gender, race, and income
status. It is particularly important that this study included
clinics with high proportions of non-white patients and
those with low income; these two demographic groups
have been under-represented in OA clinical trials, and
some studies have shown that these groups have lower re-
ferrals to and use of some OA-related treatment compo-
nents [17,38,39,58-60]. Clinic samples also varied in terms
of self-reported overall health, with 20%-35% rating their
health as fair or poor. This is important because overall
health status may impact response to the patient behavioral
intervention or the effectiveness of the provider-based
intervention. In particular, it may be more challenging for
providers to adequately address OA-specific issues for pa-
tients who also have multiple comorbid conditions. With
regard to OA-specific characteristics, there was not much
between-clinic variation in presence of knee OA (≥90% at
all clinics), but there was substantial between-clinic vari-
ation in diagnosis of hip OA (26%-68%) and diagnosis of
both knee and hip OA 23%-61%. Some clinics with a higher
prevalence of hip OA were also those in which the average
participant age was higher (e.g. clinics #2, #3, and #7). Not
surprisingly, the duration of arthritis symptoms was also
longer in several of the clinics with the highest average pa-
tient age (e.g. clinics 2, 3, and 4). There was between-clinic
variation in WOMAC scores, ranging from 34.7-44.2 , on a
scale of 0–96; this range likely reflects clinically meaningful
differences in average symptom severity across these clinic
samples [61].
Finally, we also observed substantial between-clinic
variation in some of the self-reported OA treatment use
variables. Although the majority of patients at all clinics
reported using pain medications for managing OA, there
was notable between-clinic variation for use of some
specific medication classes. This is not surprising since
there is no standard algorithm for pharmacological treat-
ment of OA [13,15,62], and patients have differential re-
sponse to various pain medications. There were also
variations in use of non-pharmacological therapies. In
particular, there was substantial between-clinic variation
in patients who reported ever seeing a physical therapist,
both for knee and hip OA. The evidence base for phys-
ical therapy as a treatment for knee OA is well estab-
lished [13-16], but less than 1/3 of patients at half of
PRIMO study clinics reported ever having received this
treatment, despite the fact that average symptom dura-
tions were 8–13 years. In addition, although 40%-64% ofpatients with knee OA reported using some type of knee
brace, much smaller proportions (0%-18%) reported
using a more supportive type of brace with metal sup-
ports. Although there is some conflicting evidence re-
garding the effectiveness of braces for knee OA [63],
these results may reflect underutilization of this treat-
ment option. We did observe a tendency for patients at
some clinics to report greater use across different cat-
egories of non-pharmacological treatments. For example,
clinics #9 and #10 had among the highest proportions of
patients reporting receipt of physical therapy and knee
braces (both in general and with metal supports), as well
as receipt of knee and hip injections. Interestingly, these
two clinics also had the lowest proportions of patients
reporting fair or poor health, suggesting that OA-
specific treatments may be more highly utilized among
patients with fewer competing health problems. Overall,
PRIMO data reflect significant variation in the use of
OA therapies – particularly non-pharmacological ones -
across different primary care settings. This may be partly
due to the lack of practical guidance in existing OA
treatment recommendations for when particular treat-
ments are best utilized [64].
There are several limitations to this study. First, all
data were self-reported, and there may be errors in pa-
tients’ recall of past OA treatment use. However, there is
not a reliable method for obtaining objective data of this
nature, and we have no reason to suspect that recall bias
would be differential across clinic sites. Second, although
we believe the practices chosen for this study are repre-
sentative of broader primary care practices in the study
region, all practices were part of one health care
organization, and it is possible that these clinics, their
patient populations and their patterns of OA treatment
may differ from other health care settings. Similarly, the
recruitment-related data describe our experiences with
this particular clinical trial, and other studies may differ
in rates of patient eligibility, enrollment and other
process variables. Third, we described the number and
types of providers at the time enrollment began at each
clinic, and in some cases there may have been subse-
quent personnel changes. However, we know of no large
changes in numbers of providers at PRIMO clinics dur-
ing the study period. Fourth, although we asked partici-
pants whether they had ever received physical therapy
care for knee or hip OA, we did not assess whether par-
ticipants had received exercise instructions from other
providers. Therefore we may have underestimated the
proportions of patients who received some exercise-
related recommendations, though other research sug-
gests this type of patient education may be infrequent in
primary care [26]. Fifth, in this pragmatic, effectiveness
study we did not obtain new radiographs or MRIs to as-
certain OA diagnoses but rather recruited patients who
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tine clinical care. Therefore specific criteria used to diag-
nose OA based on imaging may have differed across
clinicians. Sixth, because OA is not always documented
in the medical record, some patients in these Duke
healthcare system clinics with hip or knee OA may have
been inadvertently excluded from potential contact for
this study.
Conclusions
In summary, these data show both the challenges and im-
portant advantages of conducting practice-based research,
particularly including diverse primary care clinics. Although
PRIMO study clinics were part of one health care system,
they varied considerably, as did participants enrolled in the
study. It is particularly important that we were able to en-
roll participants that differed in terms of overall health
status, income, OA symptom severity, and baseline OA
treatment use, as these may all impact intervention re-
sponse. Inclusion of differing clinics will also allow assess-
ment of practical aspects of implementing a provider-based
OA intervention across different primary care settings. Fi-
nally, these results illustrate specific challenges of conduct-
ing pragmatic trials that actively recruit patients based on
electronic medical record data. Two main challenges were
variability in diagnostic coding and the volume of time re-
quired to review medical records for eligibility criteria. Al-
though this study focused on OA, these challenges would
likely apply to many other chronic health problems since
coding variability exists for many conditions [65-68]. The
increased availability of electronic medical records holds
great promise for clinical and health services research, but
there is a need for more efficient and standardized pro-
cesses that facilitate identification and recruitment of pa-
tients for these kinds of pragmatic studies.
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